Initial Single-center Experience of PIPAC in Patients With Unresectable Peritoneal Metastasis
Initial Single-center Experience of PIPAC in Patients With Unresectable Peritoneal Metastasis
复制标题
DOI：
10.1016/j.ciresp.2020.06.020
复制
发表时间：
2021-04-30
期刊：
影响因子：
1.9
通讯作者：
Galindo Alvarez, Julio
中科院分区：
文献类型：
--
作者：
Cuadrado Ayuso, Marta;Cabanas Montero, Jacobo;Galindo Alvarez, Julio
简介：腹膜癌病仍然是一种预后不良且治疗选择有限的疾病。加压腹腔内气溶胶化疗 (PIPAC) 已被开发为一种低发病率腹腔内化疗的新工具。本研究的目的是评估我院腹膜癌患者使用PIPAC的初步经验。方法：于某三级公立医院进行2019年1月至2020年2月的前瞻性研究。记录原发肿瘤、腹水量、PCI、化疗方案、手术时间、发病率、住院时间和死亡率进行分析。结果：我们分析了 5 名患者进行的 9 次 PIPAC 手术。 PCI 中位数为 27.6 (24-35)。中位手术时间为 93 分钟 (70-125)。 9 次手术中仅发生 1 次不良事件 (Clavien-Dindo II)。住院时间中位数为 2 天 (1-4)。死亡率为0%。结论：PIPAC似乎是治疗腹膜癌病的一种可行且安全的手术，发病率低，住院时间短。 (C) 2020 年 AEC。由 Elsevier Espana, S.L.U. 出版版权所有。
Introduction: Peritoneal carcinomatosis remains a condition with poor prognosis and limited therapeutic options. Pressurized Intrapertioneal Aerosol Chemotherapy (PIPAC) has been developed as a new tool for delivering intraperitoneal chemotherapy with low morbidity. The aim of this study was to evaluate the initial experience of PIPAC in patients with peritoneal carcinomatosis at our hospital.Methods: A prospective study between January 2019 and February 2020 was carried at a tertiary public hospital. Primary tumor, ascites volume, PCI, chemotherapy regimen, operative time, morbidity, length of hospital stay and mortality were recorded for analysis.Results: We analyzed 9 PIPAC procedures performed in 5 patients. Median PCI was 27.6 (24-35). Median surgical time was 93 minutes (70-125). Only one adverse event occurred out of 9 procedures (Clavien-Dindo II). Median length of hospital stay was 2 days (1-4). Mortality was 0%.Conclusion: PIPAC seems to be a feasible and safe procedure to treat peritoneal carcinomatosis, with low morbidity and short hospital stay. (C) 2020 AEC. Published by Elsevier Espana, S.L.U. All rights reserved.